Study of a new drug with hormone therapy before breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial tests a new drug called culmerciclib when given with hormone therapy before breast cancer surgery. The goal is to see if this combination can shrink tumors and improve outcomes for patients with hormone-receptor-positive, HER2-negative breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have been diagnosed with early-stage breast cancer that has not been treated yet, and it is hormone-receptor-positive and HER2-negative.
- Your tumor is larger than 2 centimeters or has spread to nearby lymph nodes.
- You have not had chemotherapy or hormone therapy for breast cancer before.
- You are generally healthy enough to undergo treatment, with normal heart, blood, liver, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests a combination of a CDK4/6 inhibitor (a type of targeted therapy) with hormone therapy given before surgery for early-stage breast cancer that is hormone receptor-positive and HER2-negative. It aims to see if this approach can shrink tumors and improve outcomes.
This study tests a new drug called Culmerciclib for women with a certain type of advanced breast cancer that has both hormone receptors and HER2. It’s for patients whose cancer has been stable on at least 4 cycles of prior therapy.
This trial tests a new drug combination (culmerciclib, anlotinib, and hormone therapy) for people with HR-positive, HER2-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink brain tumors and control the cancer for as long as possible.
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
Hear when a new Hormone-receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.